Observational study to assess cognitive functions, white matter hyperintensities, cerebral blood flow and fractional anisotropy in treatment-naive middle-aged hypertensive patients compared to normotensive controls and to assess the impact of 12-weeks single pill Perindopril/Indapamide treatment on those domains to improve personalized antihypertensive therapy

Sechenov University0 个研究点目标入组 64 人开始时间: 2020年2月6日最近更新: 2020年10月19日

试验速览

•Hypertension group:
•1. Age 40-59 years
•2. Office SBP – 140–179 mmHg and/or DBP – 90–109 mmHg
•3. Presence of at least one hypertension-mediated organ damage (heart – left ventricular hypertrophy assessed by echocardiogram, blood vessels – atherosclerotic plaques assessed by triplex scanning of the brachiocephalic arteries, kidneys – microalbuminuria and/or glomerular filtration rate according to CKD-EPI between 30-60 ml/min/1.73 m²)
•4. Lack of antihypertensive treatment
•Control group
•1. Healthy men and women
•2. Age 40-59 years
•3. Absence of hypertension

•1. Body mass index = 40 kg/m²
•2. Pregnancy, lactation
•3. Clinically significant heart disease (myocardial infarction, 2nd and 3rd degree atrio-ventricular block without artificial pacemaker, sinoatrial block, sick sinus syndrome, hypertrophic cardiomyopathy, aortic and mitral stenosis, chronic heart failure, angina pectoris)
•4. Clinically significant liver disease
•5. Clinically significant kidney disease (GFR according to CKD-EPI <30 ml/min / 1.73 m², hemodialysis, anuria)
•6. Clinically significant respiratory organ disease (including bronchial asthma and chronic obstructive pulmonary disease)
•7. Clinically significant immunological disease
•8. Clinically significant endocrine disease (including diabetes mellitus)
•9. Secondary hypertension
•11. Mental illness and disorders, dementia, drug and alcohol abuse
•12. Severe peripheral vascular diseases (including Raynaud's syndrome)
•13. Metabolic acidosis
•14. Refractory hypokalemia
•15. Clinically significant neurological diseases (including stroke and transient ischemic attack)
•16. Surgical operation in the previous 3 months (excluding dental or plastic surgery)
•17. Use of any medication (including regular intake of antihypertensive treatment) that could have affected the results of the study for 12 weeks before enrollment, at the time of enrollment and until the end of the study

发起方

Sechenov University